Skip to main content
Top
Published in: BMC Infectious Diseases 1/2015

Open Access 01-12-2015 | Research article

No development of ciprofloxacin resistance in the Haemophilus species associated with pneumonia over a 10-year study

Authors: Josef Yayan, Beniam Ghebremedhin, Kurt Rasche

Published in: BMC Infectious Diseases | Issue 1/2015

Login to get access

Abstract

Background

The widespread overuse of antibiotics promotes the development of antibiotic resistance in bacteria, which can cause severe illness and constitutes a major public health concern. Haemophilus species are a common cause of community- and nosocomial-acquired pneumonia. The antibiotic resistance of these Gram-negative bacteria can be prevented through the reduction of unnecessary antibiotic prescriptions, the correct use of antibiotics, and good hygiene and infection control. This article examines, retrospectively, antibiotic resistance in patients with community- and nosocomial-acquired pneumonia caused by Haemophilus species.

Methods

The demographic, clinical, and laboratory data of all patients with community- and nosocomial-acquired pneumonia caused by Haemophilus species were collected from the hospital charts at the HELIOS Clinic, Witten/Herdecke University, Wuppertal, Germany, within a study period from 2004 to 2014. Antimicrobial susceptibility testing was performed for the different antibiotics that have been consistently used in the treatment of patients with pneumonia caused by Haemophilus species.

Results

During the study period of January 1, 2004, to August 12, 2014, 82 patients were identified with community- and nosocomial-acquired pneumonia affected by Haemophilus species. These patients had a mean age of 63.8 ± 15.5 (60 [73.2 %, 95 % CI 63.6 %–82.8 %] males and 22 [26.8 %, 95 % CI 17.2 %–36.4 %] females). Haemophilus species had a high resistance rate to erythromycin (38.3 %), ampicillin (24.4 %), piperacillin (20.8 %), cefuroxime (8.5 %), ampicillin-sulbactam (7.3 %), piperacillin-sulbactam (4.3 %), piperacillin-tazobactam (2.5 %), cefotaxime (2.5 %), and levofloxacin (1.6 %). In contrast, they were not resistant to ciprofloxacin in patients with pneumonia (P = 0.016).

Conclusion

Haemophilus species were resistant to many of the typically used antibiotics. Resistance toward ciprofloxacin was not detected in patients with pneumonia caused by Haemophilus species.
Literature
1.
go back to reference Lichtenegger S, Bina I, Roier S, Bauernfeind S, Keidel K, Schild S, et al. Characterization of lactate utilization and its implication on the physiology of Haemophilus influenzae. Int J Med Microbiol. 2014;304:490–8.CrossRefPubMedPubMedCentral Lichtenegger S, Bina I, Roier S, Bauernfeind S, Keidel K, Schild S, et al. Characterization of lactate utilization and its implication on the physiology of Haemophilus influenzae. Int J Med Microbiol. 2014;304:490–8.CrossRefPubMedPubMedCentral
2.
go back to reference Frickmann H, Podbielski A, Essig A, Schwarz NG, Zautner AE. Difficulties in species identification within the genus Haemophilus—A pilot study addressing a significant problem for routine diagnostics. Eur J Microbiol Immunol (Bp). 2014;4:99–105.CrossRef Frickmann H, Podbielski A, Essig A, Schwarz NG, Zautner AE. Difficulties in species identification within the genus Haemophilus—A pilot study addressing a significant problem for routine diagnostics. Eur J Microbiol Immunol (Bp). 2014;4:99–105.CrossRef
3.
go back to reference Qvarfordt I, Riise GC, Andersson BA, Larsson S. Lower airway bacterial colonization in asymptomatic smokers and smokers with chronic bronchitis and recurrent exacerbations. Respir Med. 2000;94:881–7.CrossRefPubMed Qvarfordt I, Riise GC, Andersson BA, Larsson S. Lower airway bacterial colonization in asymptomatic smokers and smokers with chronic bronchitis and recurrent exacerbations. Respir Med. 2000;94:881–7.CrossRefPubMed
4.
go back to reference Amin AN, Cerceo EA, Deitelzweig SB, Pile JC, Rosenberg DJ, Sherman BM. The hospitalist perspective on treatment of community-acquired bacterial pneumonia. Postgrad Med. 2014;126:18–29.CrossRefPubMed Amin AN, Cerceo EA, Deitelzweig SB, Pile JC, Rosenberg DJ, Sherman BM. The hospitalist perspective on treatment of community-acquired bacterial pneumonia. Postgrad Med. 2014;126:18–29.CrossRefPubMed
5.
go back to reference Alpuche C, Garau J, Lim V. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens. Int J Antimicrob Agents. 2007;30 Suppl 2:S135–8.CrossRefPubMed Alpuche C, Garau J, Lim V. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens. Int J Antimicrob Agents. 2007;30 Suppl 2:S135–8.CrossRefPubMed
6.
go back to reference Sahm DF, Brown NP, Thornsberry C, Jones ME. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad Med. 2008;120(3 Suppl 1):16–24.CrossRefPubMed Sahm DF, Brown NP, Thornsberry C, Jones ME. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad Med. 2008;120(3 Suppl 1):16–24.CrossRefPubMed
7.
go back to reference Rennie RP, Ibrahim KH. Antimicrobial resistance in Haemophilus influenzae: How can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program. Clin Infect Dis. 2005;41 Suppl 4:S234–8.CrossRefPubMed Rennie RP, Ibrahim KH. Antimicrobial resistance in Haemophilus influenzae: How can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program. Clin Infect Dis. 2005;41 Suppl 4:S234–8.CrossRefPubMed
8.
go back to reference Housset B. Definition of low respiratory tract infections. [In French.]. Med Mal Infect. 2006;36(11–12):538–45.CrossRefPubMed Housset B. Definition of low respiratory tract infections. [In French.]. Med Mal Infect. 2006;36(11–12):538–45.CrossRefPubMed
10.
go back to reference Niederman MS, Mandell LA, Anzeuto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–54.CrossRefPubMed Niederman MS, Mandell LA, Anzeuto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–54.CrossRefPubMed
11.
go back to reference Watkins RR, Lemonovich TL. Diagnosis and management of community-acquired pneumonia in adults. Am Fam Physician. 2011;83:1299–306.PubMed Watkins RR, Lemonovich TL. Diagnosis and management of community-acquired pneumonia in adults. Am Fam Physician. 2011;83:1299–306.PubMed
12.
go back to reference Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI M100-S22. Wayne: Clinical and Laboratory Standards Institute; 2012. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI M100-S22. Wayne: Clinical and Laboratory Standards Institute; 2012.
14.
go back to reference Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45:493–6.PubMed Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45:493–6.PubMed
15.
go back to reference The European Committee on Antimicrobial Susceptibility Testing–EUCAST. Zone Diameter Interpretive Standards and Equivalent Minimal Inhibitory Concentration (MIC) Breakpoints for Haemophilus influenzae and Haemophilus parainfluenzae. http://ww.eucast.org. Accessed 23 January 2015. The European Committee on Antimicrobial Susceptibility Testing–EUCAST. Zone Diameter Interpretive Standards and Equivalent Minimal Inhibitory Concentration (MIC) Breakpoints for Haemophilus influenzae and Haemophilus parainfluenzae. http://​ww.​eucast.​org. Accessed 23 January 2015.
16.
go back to reference Barlett JG. Diagnosis of bacterial infections of the lung. Clin Chest Med. 1987;8:119–34. Barlett JG. Diagnosis of bacterial infections of the lung. Clin Chest Med. 1987;8:119–34.
18.
go back to reference Periti P, Mazzei T, Curti ME, for the Italian Ciprofloxacin Study Group. Efficacy and safety of high dose intravenous ciprofloxacin in the treatment of bacterial pneumonia. Int J Antimicrob Agents. 1998;10:215–22.CrossRefPubMed Periti P, Mazzei T, Curti ME, for the Italian Ciprofloxacin Study Group. Efficacy and safety of high dose intravenous ciprofloxacin in the treatment of bacterial pneumonia. Int J Antimicrob Agents. 1998;10:215–22.CrossRefPubMed
19.
go back to reference Krumpe PE, Cohn S, Garreltes J, Ramirez J, Coulter H, Haverstock D, et al. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: Ciprofloxacin versus standard antibiotic therapy. J Antimicrob Chemother. 1999;43 Suppl A:117–28.CrossRefPubMed Krumpe PE, Cohn S, Garreltes J, Ramirez J, Coulter H, Haverstock D, et al. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: Ciprofloxacin versus standard antibiotic therapy. J Antimicrob Chemother. 1999;43 Suppl A:117–28.CrossRefPubMed
20.
go back to reference Mukae H, Kawanami T, Yatera K, Yanagihara K, Yamamoto Y, Kakeya H, et al. Efficacy and safety of levofloxacin in patients with bacterial pneumonia evaluated according to the new "Clinical Evaluation Methods for New Antimicrobial Agents to Treat Respiratory Infections (Second Version)". J Infect Chemother. 2014;20:417–22.CrossRefPubMed Mukae H, Kawanami T, Yatera K, Yanagihara K, Yamamoto Y, Kakeya H, et al. Efficacy and safety of levofloxacin in patients with bacterial pneumonia evaluated according to the new "Clinical Evaluation Methods for New Antimicrobial Agents to Treat Respiratory Infections (Second Version)". J Infect Chemother. 2014;20:417–22.CrossRefPubMed
21.
go back to reference Kuo SC, Chen PC, Shiau YR, Wang HY, Lai JF 1st, Huang W, et al. Levofloxacin-resistant haemophilus influenzae, Taiwan, 2004–2010. Emerg Infect Dis. 2014;20:1386–90. Kuo SC, Chen PC, Shiau YR, Wang HY, Lai JF 1st, Huang W, et al. Levofloxacin-resistant haemophilus influenzae, Taiwan, 2004–2010. Emerg Infect Dis. 2014;20:1386–90.
22.
go back to reference Chang CM, Lauderdale TL, Lee HC, Lee NY, Wu CJ, Chen PL, et al. Colonisation of fluoroquinolone-resistant Haemophilus influenzae among nursing home residents in southern Taiwan. J Hosp Infect. 2010;75:304–8.CrossRefPubMed Chang CM, Lauderdale TL, Lee HC, Lee NY, Wu CJ, Chen PL, et al. Colonisation of fluoroquinolone-resistant Haemophilus influenzae among nursing home residents in southern Taiwan. J Hosp Infect. 2010;75:304–8.CrossRefPubMed
23.
go back to reference Bozdogan B, Tristram S, Appelbaum PC. Combination of altered PBPs and expression of cloned extended-spectrum beta-lactamases confers cefotaxime resistance in Haemophilus influenzae. J Antimicrob Chemother. 2006;57:747–9.CrossRefPubMed Bozdogan B, Tristram S, Appelbaum PC. Combination of altered PBPs and expression of cloned extended-spectrum beta-lactamases confers cefotaxime resistance in Haemophilus influenzae. J Antimicrob Chemother. 2006;57:747–9.CrossRefPubMed
24.
go back to reference Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933–51.CrossRefPubMedPubMedCentral Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933–51.CrossRefPubMedPubMedCentral
25.
go back to reference Abe K, Hoshino T, Imuta N, Nishi J, Ishiwada N. Bacterial meningitis caused by beta-lactamase-negative, ampicillin-resistant nontypeable Haemophilus influenzae in a 1-year-old girl: a case report. [In Japanese.]. Kansenshogaku Zasshi. 2014;88(3):291–6.PubMed Abe K, Hoshino T, Imuta N, Nishi J, Ishiwada N. Bacterial meningitis caused by beta-lactamase-negative, ampicillin-resistant nontypeable Haemophilus influenzae in a 1-year-old girl: a case report. [In Japanese.]. Kansenshogaku Zasshi. 2014;88(3):291–6.PubMed
26.
go back to reference Daley D, Mulgrave L, Munro R, Neville S, Smith H, Dimech W. An evaluation of the in vitro activity of piperacillin/tazobactam. Pathology. 1996;28:167–72.CrossRefPubMed Daley D, Mulgrave L, Munro R, Neville S, Smith H, Dimech W. An evaluation of the in vitro activity of piperacillin/tazobactam. Pathology. 1996;28:167–72.CrossRefPubMed
27.
go back to reference Sifuentes-Osornio J, Ruíz-Palacios GM, Jakob E, Rojas JJ, Jáuregui A, Villalobos Y, et al. Piperacillin/tazobactam in the treatment of lower respiratory tract infections: an open non-comparative and multicentered trial. J Chemother. 1994;6:197–203.CrossRefPubMed Sifuentes-Osornio J, Ruíz-Palacios GM, Jakob E, Rojas JJ, Jáuregui A, Villalobos Y, et al. Piperacillin/tazobactam in the treatment of lower respiratory tract infections: an open non-comparative and multicentered trial. J Chemother. 1994;6:197–203.CrossRefPubMed
28.
go back to reference Hirakata Y, Ohmori K, Mikuriya M, Saika T, Matsuzaki K, Hasegawa M, et al. Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone resistance-determining regions. Antimicrob Agents Chemother. 2009;53:4225–30.CrossRefPubMedPubMedCentral Hirakata Y, Ohmori K, Mikuriya M, Saika T, Matsuzaki K, Hasegawa M, et al. Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone resistance-determining regions. Antimicrob Agents Chemother. 2009;53:4225–30.CrossRefPubMedPubMedCentral
29.
go back to reference Emmi V. Guidelines for treatment of pneumonia in intensive care units. [In Italian.] Infez Med. 2005;Suppl:7–17. Emmi V. Guidelines for treatment of pneumonia in intensive care units. [In Italian.] Infez Med. 2005;Suppl:7–17.
30.
go back to reference Williams D, Perri M, Zervos MJ. Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1994;13:293–8.CrossRefPubMed Williams D, Perri M, Zervos MJ. Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1994;13:293–8.CrossRefPubMed
31.
go back to reference Van den Brande P, Vondra V, Vogel F, Schlaeffer F, Staley H, Holmes C. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. Chest. 1997;112:406–15.CrossRefPubMed Van den Brande P, Vondra V, Vogel F, Schlaeffer F, Staley H, Holmes C. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. Chest. 1997;112:406–15.CrossRefPubMed
32.
go back to reference Oh HM, Ng AW, Lee SK. Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Singapore Med J. 1996;37:255–7.PubMed Oh HM, Ng AW, Lee SK. Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Singapore Med J. 1996;37:255–7.PubMed
33.
go back to reference Perry CM, Brogden RN. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1996;52:125–58.CrossRefPubMed Perry CM, Brogden RN. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1996;52:125–58.CrossRefPubMed
34.
go back to reference Yeo SF, Chiew YF, Fung CP. Susceptibility of Haemophilus influenzae isolates with known resistance mechanisms to five cephalosporins. Chemotherapy. 1996;42:85–9.CrossRefPubMed Yeo SF, Chiew YF, Fung CP. Susceptibility of Haemophilus influenzae isolates with known resistance mechanisms to five cephalosporins. Chemotherapy. 1996;42:85–9.CrossRefPubMed
35.
go back to reference Eliopoulos GM, Moellering Jr RC. Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. Ann Intern Med. 1982;97:755–60.CrossRefPubMed Eliopoulos GM, Moellering Jr RC. Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. Ann Intern Med. 1982;97:755–60.CrossRefPubMed
36.
go back to reference Seki M, Higashiyama Y, Imamura Y, Nakamura S, Kurihara S, Izumikawa K, et al. A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia. Intern Med. 2009;48:49–55.CrossRefPubMed Seki M, Higashiyama Y, Imamura Y, Nakamura S, Kurihara S, Izumikawa K, et al. A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia. Intern Med. 2009;48:49–55.CrossRefPubMed
37.
go back to reference Blasi F, Farrell DJ, Dubreuil L. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the prospective resistant organism tracking and epidemiology for the ketolide Telithromycin study year 5 (2003–2004). Diagn Microbiol Infect Dis. 2009;63:302–8.CrossRefPubMed Blasi F, Farrell DJ, Dubreuil L. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the prospective resistant organism tracking and epidemiology for the ketolide Telithromycin study year 5 (2003–2004). Diagn Microbiol Infect Dis. 2009;63:302–8.CrossRefPubMed
38.
go back to reference Bell SM, Plowman D. Mechanisms of ampicillin resistance in Haemophilus influenzae from respiratory tract. Lancet. 1980;1(8163):279–80.CrossRefPubMed Bell SM, Plowman D. Mechanisms of ampicillin resistance in Haemophilus influenzae from respiratory tract. Lancet. 1980;1(8163):279–80.CrossRefPubMed
39.
go back to reference Thornsberry C, McDougal LK. Ampicillin-resistant Haemophilus influenzae. 1. Incidence, mechanism, and detection. Postgrad Med. 1982;71(133–6):140,144–5. Thornsberry C, McDougal LK. Ampicillin-resistant Haemophilus influenzae. 1. Incidence, mechanism, and detection. Postgrad Med. 1982;71(133–6):140,144–5.
40.
go back to reference Parker RH. Hemophilus influenzae respiratory infection in adults. 2. Treatment guidelines. Postgrad Med. 1983;73:187–91.CrossRefPubMed Parker RH. Hemophilus influenzae respiratory infection in adults. 2. Treatment guidelines. Postgrad Med. 1983;73:187–91.CrossRefPubMed
41.
go back to reference Bukvić Krajacić M, Novak P, Dumić M, Cindrić M, Paljetak HC, Kujundzić N. Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. Eur J Med Chem. 2009;44:3459–70.CrossRefPubMed Bukvić Krajacić M, Novak P, Dumić M, Cindrić M, Paljetak HC, Kujundzić N. Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. Eur J Med Chem. 2009;44:3459–70.CrossRefPubMed
42.
go back to reference Zhu B, Marinelli BA, Abbanat D, Foleno BD, Henninger TC, Bush K, et al. Synthesis and antibacterial activity of 3-O-acyl-6-O-carbamoyl erythromycin A derivatives. Bioorg Med Chem Lett. 2006;16:1054–9.CrossRefPubMed Zhu B, Marinelli BA, Abbanat D, Foleno BD, Henninger TC, Bush K, et al. Synthesis and antibacterial activity of 3-O-acyl-6-O-carbamoyl erythromycin A derivatives. Bioorg Med Chem Lett. 2006;16:1054–9.CrossRefPubMed
43.
go back to reference Bozdogan B, Appelbaum PC. Macrolide resistance in Streptococci and Haemophilus influenzae. Clin Lab Med. 2004;24:455–75.CrossRefPubMed Bozdogan B, Appelbaum PC. Macrolide resistance in Streptococci and Haemophilus influenzae. Clin Lab Med. 2004;24:455–75.CrossRefPubMed
44.
go back to reference Cizman M, Pokorn M, Seme K, Orazem A, Paragi M. The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. J Antimicrob Chemother. 2001;47:475–77.CrossRefPubMed Cizman M, Pokorn M, Seme K, Orazem A, Paragi M. The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. J Antimicrob Chemother. 2001;47:475–77.CrossRefPubMed
45.
go back to reference Almirall J, Bolíbar I, Toran P, Pera G, Boquet X, Balanzó X, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004;125:1335–42.CrossRefPubMed Almirall J, Bolíbar I, Toran P, Pera G, Boquet X, Balanzó X, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004;125:1335–42.CrossRefPubMed
46.
go back to reference Bircan A, Kaya O, Gökirmak M, Oztürk O, Sahin U, Akkaya A. C-reactive protein, leukocyte count and ESR in the assessment of severity of community-acquired pneumonia [In Turkish.]. Tuberk Toraks. 2006;54:22–9.PubMed Bircan A, Kaya O, Gökirmak M, Oztürk O, Sahin U, Akkaya A. C-reactive protein, leukocyte count and ESR in the assessment of severity of community-acquired pneumonia [In Turkish.]. Tuberk Toraks. 2006;54:22–9.PubMed
Metadata
Title
No development of ciprofloxacin resistance in the Haemophilus species associated with pneumonia over a 10-year study
Authors
Josef Yayan
Beniam Ghebremedhin
Kurt Rasche
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2015
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-015-1267-3

Other articles of this Issue 1/2015

BMC Infectious Diseases 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine